130 related articles for article (PubMed ID: 20406195)
1. Alzheimer's disease drug discovery: Abeta and beyond.
Shineman DW; Fillit HM
Curr Alzheimer Res; 2010 May; 7(3):188-9. PubMed ID: 20406195
[No Abstract] [Full Text] [Related]
2. Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.
Malter JS; Ray BC; Westmark PR; Westmark CJ
Curr Alzheimer Res; 2010 May; 7(3):200-6. PubMed ID: 20088809
[TBL] [Abstract][Full Text] [Related]
3. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease.
Hamilton A; Esseltine JL; DeVries RA; Cregan SP; Ferguson SS
Mol Brain; 2014 May; 7():40. PubMed ID: 24886239
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery for Alzheimer's disease: filling the pipeline.
Horton AR; Fillit HM
Curr Alzheimer Res; 2007 Dec; 4(5):501-2. PubMed ID: 18220510
[No Abstract] [Full Text] [Related]
5. Metabotropic Glutamate Receptors in Alzheimer's Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future.
Srivastava A; Das B; Yao AY; Yan R
J Alzheimers Dis; 2020; 78(4):1345-1361. PubMed ID: 33325389
[TBL] [Abstract][Full Text] [Related]
6. Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression.
Findley CA; Bartke A; Hascup KN; Hascup ER
ASN Neuro; 2019; 11():1759091419855541. PubMed ID: 31213067
[TBL] [Abstract][Full Text] [Related]
7. To think or not to think: synaptic activity and Abeta release.
Schroeder BE; Koo EH
Neuron; 2005 Dec; 48(6):873-5. PubMed ID: 16364890
[TBL] [Abstract][Full Text] [Related]
8. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals.
Kim SH; Fraser PE; Westaway D; St George-Hyslop PH; Ehrlich ME; Gandy S
J Neurosci; 2010 Mar; 30(11):3870-5. PubMed ID: 20237257
[TBL] [Abstract][Full Text] [Related]
9. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.
Fukami S; Watanabe K; Iwata N; Haraoka J; Lu B; Gerard NP; Gerard C; Fraser P; Westaway D; St George-Hyslop P; Saido TC
Neurosci Res; 2002 May; 43(1):39-56. PubMed ID: 12074840
[TBL] [Abstract][Full Text] [Related]
10. Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Folch J; Petrov D; Ettcheto M; Abad S; Sánchez-López E; García ML; Olloquequi J; Beas-Zarate C; Auladell C; Camins A
Neural Plast; 2016; 2016():8501693. PubMed ID: 26881137
[TBL] [Abstract][Full Text] [Related]
11. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
Cribbs DH; Agadjanyan MG
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
[No Abstract] [Full Text] [Related]
12. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.
Caraci F; Molinaro G; Battaglia G; Giuffrida ML; Riozzi B; Traficante A; Bruno V; Cannella M; Merlo S; Wang X; Heinz BA; Nisenbaum ES; Britton TC; Drago F; Sortino MA; Copani A; Nicoletti F
Mol Pharmacol; 2011 Mar; 79(3):618-26. PubMed ID: 21159998
[TBL] [Abstract][Full Text] [Related]
13. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
Ising C; Stanley M; Holtzman DM
Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
[TBL] [Abstract][Full Text] [Related]
14. Proceedings of the 10th International Conference on Alzheimer's Drug Discovery. September 14-15, 2009. Jersey City, New Jersey, USA.
Curr Alzheimer Res; 2010 May; 7(3):188-279. PubMed ID: 20687240
[No Abstract] [Full Text] [Related]
15. Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition.
Shah D; Praet J; Latif Hernandez A; Höfling C; Anckaerts C; Bard F; Morawski M; Detrez JR; Prinsen E; Villa A; De Vos WH; Maggi A; D'Hooge R; Balschun D; Rossner S; Verhoye M; Van der Linden A
Alzheimers Dement; 2016 Sep; 12(9):964-976. PubMed ID: 27107518
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease.
Caraci F; Nicoletti F; Copani A
Curr Opin Pharmacol; 2018 Feb; 38():1-7. PubMed ID: 29278824
[TBL] [Abstract][Full Text] [Related]
17. Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation.
Simoni E; Bartolini M; Abu IF; Blockley A; Gotti C; Bottegoni G; Caporaso R; Bergamini C; Andrisano V; Cavalli A; Mellor IR; Minarini A; Rosini M
Future Med Chem; 2017 Jun; 9(10):953-963. PubMed ID: 28632446
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse.
Ronesi JA; Huber KM
Sci Signal; 2008 Feb; 1(5):pe6. PubMed ID: 18272470
[TBL] [Abstract][Full Text] [Related]
19. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses.
Almeida CG; Tampellini D; Takahashi RH; Greengard P; Lin MT; Snyder EM; Gouras GK
Neurobiol Dis; 2005 Nov; 20(2):187-98. PubMed ID: 16242627
[TBL] [Abstract][Full Text] [Related]
20. Disrupting beta-amyloid aggregation for Alzheimer disease treatment.
Estrada LD; Soto C
Curr Top Med Chem; 2007; 7(1):115-26. PubMed ID: 17266599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
